Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

BCL2

2 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology

Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer

Xie J, Wang S, Liu J, et al.

Apoptosis

This study investigates the interaction between mutated KRAS and AGO2 in colorectal cancer (CRC), a mechanism that impairs AGO2 function and promotes tumor progression. Researchers developed peptide-gold nanoparticles (Au-pep) to specifically disrupt this interaction, which restored microRNA expression, particularly let-7c-5p. This restoration led to the downregulation of key oncogenic drivers such as KRAS, c-Myc, and Bcl2, suppressing the growth of KRAS-mutated CRC cells and inducing apoptosis. Furthermore, this approach sensitized cells to existing treatments, including 5-fluorouracil and immunotherapy, by regulating ABCC5 and PD-L1.

Clinical

Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial

Xu PP, Song YQ, Shen JZ, et al.

JAMA

A randomized, placebo-controlled phase 3 clinical trial investigated the addition of tucidinostat, a histone deacetylase inhibitor, to standard R-CHOP in patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma (DEL). The study demonstrated a significant improvement in event-free survival (EFS) in the tucidinostat group, with a 28% lower risk of events and a two-year EFS rate of 60.3% versus 50.5% for the placebo group. The complete response rate was also higher (73.0% vs 61.8%). Although increased toxicity was observed with tucidinostat, it was generally manageable.